Aegis Capital Maintains Buy on DarioHealth, Lowers Price Target to $28
Aegis Capital analyst Nathan Weinstein maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $35 to $28.
DRIO: Dario’s RPM Accelerating
By John Vandermosten, CFA
NASDAQ:DRIO
READ THE FULL DRIO RESEARCH REPORT
Why Is DarioHealth Falling After Earnings?
DarioHealth Corp (NASDAQ:DRIO) reported second-quarter FY21 revenue growth of 194% year-on-year to $5.26 million, beating the analyst consensus of $5.11 million.…
Recap: DarioHealth Q2 Earnings
Shares of DarioHealth (NASDAQ:DRIO) fell 0.5% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were unchanged 0.00% over the past year to ($0.68), which beat the estimate of ($0.85).
DarioHealth Q2 EPS $(0.99) Misses $(0.85) Estimate, Sales $5.26M Beat $5.11M Estimate
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.85) by 16.47 percent. This is a 45.59 percent decrease over losses of $(0.68) per share from the
Earnings Scheduled For August 16, 2021
Companies Reporting Before The Bell
• Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter.
• Data Storage (NASDAQ:DTST) is expected to report earnings for its second quarter.
DarioHealth Says Presents New Study ‘Demonstrating Significant Clinical Impact Of Personalized Digital Interventions Based On Real-Time Data’
DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced a new study at the American Association of Diabetes Care and Education Specialists (ADCES) annual conference
Dario Health Reports Co. Was Selected As A Digital Health Provider By Alabama Regional Medical Services, No Terms Disclosed
DarioHealth Corp. (NASDAQ:DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as a digital health provider by Alabama Regional Medical Services (ARMS), a Federally Qualified
DRIO: Dario’s Evolving Strategic Vision
By John Vandermosten, CFA
NASDAQ:DRIO
READ THE FULL DRIO RESEARCH REPORT
DarioHealth Highlights Launch Of 3 New Employer Client Contracts, No Terms Disclosed
DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, today announced the launch of three new employer client contracts, including one global partnership, for the Company's new